Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Guardat en:

Dades bibliogràfiques
Autors principals:	Matteo Santoni, Zin Myint, Thomas Büttner, Hideki Takeshita, Y. Okada, Elaine T. Lam, Danielle Gilbert, Zsófia Kürönya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, ROBERT COLEMAN KEMP, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina‐Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popović, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindřich Kopecký, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino Marques Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta
Format:	Artigo
Idioma:	anglès
Publicat:	2023
Accés en línia:	https://doi.org/10.1007/s00262-023-03469-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Internet